Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Saki Ujike"'
Autor:
Kento Sonoda, Sudarma Bogahawaththa, Akito Katayama, Saki Ujike, Sae Kuroki, Naho Kitagawa, Kohichi Hirotsuru, Norio Suzuki, Toshio Miyata, Shin-ichi Kawaguchi, Tadayuki Tsujita
Publikováno v:
ACS Pharmacol Transl Sci
[Image: see text] Hypoxia-inducible factor-α (HIF-α) activation has shown promising results in the treatment of ischemia, such as stroke, myocardial infarction, and chronic kidney disease. A number of HIF-α activators have been developed to improv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9bc97e3d5325117dacf642c693d734cb
https://doi.org/10.1021/acsptsci.2c00002
https://doi.org/10.1021/acsptsci.2c00002
Autor:
Kento Sonoda, Saki Ujike, Akito Katayama, Norio Suzuki, Shin-ichi Kawaguchi, Tadayuki Tsujita
Publikováno v:
Bioorganicmedicinal chemistry. 73
Hypoxia-inducible factor (HIF) activators aid the treatment of renal anemia and ischemia. Recently, PyrzA (5-(1-acetyl-5-phenylpyrazolidin-3-ylidene)-1,3-dimethylbarbituric acid), a HIF activator by PHD inhibition without a 2-oxoglutarate moiety was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8bcb04a63b472646bcd0488577fcf1c0
https://pubmed.ncbi.nlm.nih.gov/36198217
https://pubmed.ncbi.nlm.nih.gov/36198217
Autor:
Kento Sonoda, Sudarma Bogahawaththa, Akito Katayama, Saki Ujike, Sae Kuroki, Naho Kitagawa, Kohichi Hirotsuru, Norio Suzuki, Toshio Miyata, Shin-ichi Kawaguchi, Tadayuki Tsujita
Publikováno v:
ACS Pharmacol Transl Sci
Hypoxia-inducible factor-α (HIF-α) activation has shown promising results in the treatment of ischemia, such as stroke, myocardial infarction, and chronic kidney disease. A number of HIF-α activators have been developed to improve the symptoms of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::374a66a056feb35b40631dd0184182eb
https://europepmc.org/articles/PMC9274765/
https://europepmc.org/articles/PMC9274765/
